Transcranial focused ultrasound could enable research into consciousness, a research team has suggested, providing a roadmap ...
We don't precisely know how the physical matter in our brains translates into thoughts, sensations, and feelings. But an ...
This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation ...
SAINT LOUIS - A new treatment for depression and obsessive-compulsive disorder is bringing hope to local ...
BrainsWay’s SWIFT depression protocol consists of an acute phase of five treatment sessions (ten minutes each) per day for ...
The field of epilepsy research has rapidly evolved with an appreciation that seizures arise from dysfunctions in distributed ...
Introduction Mental disorders affect nearly one billion people worldwide, posing major challenges to public health. While conventional treatments like psychotherapy and pharmacotherapy are effective ...
Detailed price information for Brainsway Ltd ADR (BWAY-Q) from The Globe and Mail including charting and trades.
Real-world evidence supporting the expanded approval demonstrated a 66.1% response rate in adolescents with major depressive disorder. The Food and Drug Administration (FDA) has cleared BrainsWay’s ...
BrainsWay’s Deep TMS [Image courtesy of BrainsWay] BrainsWay announced today that the FDA granted a label expansion for its deep transcranial magnetic stimulation (Deep TMS) system. Expanded FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback